From Data to Decisions: Analyzing Automated Insulin Delivery Reports | Recording-From Data to Decisions: Analyzing Automated Insulin Delivery Reports

Video Transcription

Video Summary

This webinar, supported by the American Diabetes Association and Medtronix, focused on interpreting reports from automated insulin delivery (AID) systems to enhance diabetes care. Expert speakers from endocrinology and pharmacy discussed the ADA guidelines recommending AID systems as preferred insulin delivery for people with type 1 and insulin-requiring type 2 diabetes, emphasizing safe use and personalized device choice. <br /><br />Key points included initiating AID therapy with a team-based approach, insurance considerations, and training patients effectively. Speakers reviewed major FDA-approved AID platforms—Medtronic 780G, Omnipod 5, Tandem Control-IQ, Beta Bionics, and others—highlighting the importance of focusing on summary or dashboard reports for efficient clinical interpretation. A four-step clinical framework was shared: ensuring >90% AID use, assessing time in range and hypoglycemia, identifying glycemic patterns, and targeting key device settings (e.g., insulin-to-carb ratio, correction factor, glucose targets) for optimization.<br /><br />Through case examples, the presenters stressed individualized adjustments, patient education on bolusing and hypoglycemia treatment, and addressing connectivity issues. Discussions covered expanding AID use beyond type 1 diabetes, managing insurance barriers, and recognizing no one-size-fits-all in device selection. The webinar concluded with Q&A, highlighting practical tips to integrate AID data into clinical decision-making for improved glycemic outcomes and quality of life.

Keywords

automated insulin delivery

AID systems

type 1 diabetes

type 2 diabetes

ADA guidelines

Medtronic 780G

Omnipod 5

Tandem Control-IQ

glycemic optimization